DSLT for Reducing Medication in Glaucoma

Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Medication Burden in Medically Controlled Patients With Ocular Hypertension or Primary Open Angle Glaucoma

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma.

The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT.

Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.

Study Overview

• Status: Recruiting
• Conditions: Primary Open Angle Glaucoma; Ocular Hypertension
• Intervention / Treatment: Device: Voyager DSLT

• Study Type: Observational
• Enrollment (Estimated): 60

Contacts and Locations

• Study Contact: Name: Renee Bondurant; Phone Number: 727-450-4668; Email: Renee.Bondurant@eyespecialist.com

Study Locations

• United States
  • Florida
    • Largo, Florida, United States, 33770
      • Recruiting
      • The Eye Institute of West Florida
      • Contact: Renee Bondurant; Phone Number: 727-450-4668; Email: Renee.Bondurant@eyespecialist.com
      • Principal Investigator: Neel Desai, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adults with ocular hypertension or POAG undergoing DSLT treatment in one or both eyes.

Description

Inclusion Criteria:

• Adult patients scheduled to undergo DSLT treatment in one or both eyes.

  • Diagnosis of ocular hypertension or primary open angle glaucoma (POAG).
• Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg.

Exclusion Criteria:

• Previous glaucoma surgeries/interventions:

  • Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).
• Patients who have undergone cataract surgery within the prior 2 years.

• Secondary glaucoma:

  • Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.
• Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduction in the number of glaucoma medications required to maintain target intraocular pressure (IOP)	The primary outcome will be assessed by comparing the number of medications needed to maintain target IOP before and after DSLT treatment.	6 months post-DSLT treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in intraocular pressure (IOP) from baseline	IOP will be measured using Goldmann applanation tonometry at each follow-up visit.	6 months post-DSLT treatment
Proportion of eyes needing medication stratified by number of IOP medications required		6 months post-DSLT treatment
Number and type of Secondary surgical interventions		6 months post-DSLT treatment

Collaborators and Investigators

• Sponsor: The Eye Institute of West Florida
• Collaborators: Sengi
• Investigators: Principal Investigator: Neel Desai, MD, The Eye Institute of West Florida

Study record dates

Study Major Dates

• Study Start (Actual): February 10, 2026
• Primary Completion (Estimated): January 26, 2027
• Study Completion (Estimated): January 26, 2027

Study Registration Dates

• First Submitted: January 29, 2026
• First Submitted That Met QC Criteria: January 29, 2026
• First Posted (Actual): February 5, 2026

Study Record Updates

• Last Update Posted (Actual): April 20, 2026
• Last Update Submitted That Met QC Criteria: April 17, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Glaucoma; Glaucoma, Open-Angle; Ocular Hypertension
• Other Study ID Numbers: ND-25-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes